Patents by Inventor Sandip Mehta
Sandip Mehta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250144013Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: ApplicationFiled: January 10, 2025Publication date: May 8, 2025Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
-
Patent number: 12226526Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: GrantFiled: August 8, 2024Date of Patent: February 18, 2025Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
-
Patent number: 12194143Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water, a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: GrantFiled: August 8, 2024Date of Patent: January 14, 2025Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
-
Publication number: 20240398700Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water, a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: ApplicationFiled: August 8, 2024Publication date: December 5, 2024Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
-
Publication number: 20240390268Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: ApplicationFiled: August 8, 2024Publication date: November 28, 2024Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
-
Publication number: 20240374516Abstract: A ready to use oral pharmaceutical suspension that includes dasatinib or a pharmaceutically acceptable salt thereof, a suspending agent, a wetting agent, a binder or filler, a buffering agent in an amount sufficient to provide a pH of from about 4 to about 8 and water.Type: ApplicationFiled: July 23, 2024Publication date: November 14, 2024Applicant: ONCOSOL LIMITEDInventors: SANDIP MEHTA, MANISHKUMAR UMRETHIA, JAYANTA MANDAL
-
Publication number: 20240366588Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.Type: ApplicationFiled: May 10, 2024Publication date: November 7, 2024Applicants: FTF PHARMA PRIVATE LIMITED, LM MANUFACTURING LIMITEDInventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
-
Patent number: 12097284Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: GrantFiled: February 15, 2024Date of Patent: September 24, 2024Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
-
Patent number: 12097285Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: GrantFiled: February 15, 2024Date of Patent: September 24, 2024Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
-
Patent number: 12083222Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an anti-cancer active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the anti-cancer active pharmaceutical ingredient is selected from ibrutinib, nilotinib, dasatinib, sunitinib, sorafenib, erlotinib, and capecitabine.Type: GrantFiled: August 16, 2019Date of Patent: September 10, 2024Assignee: ONCOSOL LIMITEDInventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
-
Publication number: 20240293393Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.Type: ApplicationFiled: May 2, 2024Publication date: September 5, 2024Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
-
Publication number: 20240216373Abstract: Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for administration. Further, dispersion of Imatinib solid oral dosage forms may not administer correct and consistent dose of medicine every time. The present invention therefore provides liquid dosage forms of Imatinib which correctly and consistently administers correct dose of drug to the patients.Type: ApplicationFiled: January 16, 2024Publication date: July 4, 2024Inventors: Sandip MEHTA, Vijay PATEL, Manish UMRETHIA, Jayanta Kumar MANDAL
-
Publication number: 20240207175Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: ApplicationFiled: February 15, 2024Publication date: June 27, 2024Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
-
Patent number: 12016857Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.Type: GrantFiled: May 2, 2023Date of Patent: June 25, 2024Assignees: FTF PHARMA PRIVATE LIMITED, LM MANUFACTURING LTD.Inventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
-
Publication number: 20240197625Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: ApplicationFiled: February 15, 2024Publication date: June 20, 2024Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
-
Publication number: 20240165024Abstract: Disclosed herein is a pharmaceutical oral suspension, comprising: mycophenolate mofetil in an amount of about 200 mg/mL; one or more cosolvents comprising ethanol, a polyethylene glycol, a sorbitol, glycerin, propylene glycol, benzyl alcohol, or a combination thereof in an amount of from about 5% w/w to about 30% w/w; one or more pharmaceutically acceptable excipients selected from a suspending agent, a preservative, a sweetener, an antifoaming agent, a wetting agent, a buffering agent, and a flavoring agent; and a vehicle comprising water. The pharmaceutical oral suspension has improved stability, palatability with high dose of active ingredient.Type: ApplicationFiled: January 25, 2024Publication date: May 23, 2024Inventors: Sandip MEHTA, Manish UMRETHIA, Henil PATEL, Jayanta Kumar MANDAL
-
Patent number: 11957681Abstract: Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for administration. Further, dispersion of Imatinib solid oral dosage forms may not administer correct and consistent dose of medicine every time. The present invention therefore provides liquid dosage forms of Imatinib which correctly and consistently administers correct dose of drug to the patients.Type: GrantFiled: July 26, 2018Date of Patent: April 16, 2024Assignee: SHORLA PHARMA LIMITEDInventors: Sandip Mehta, Vijay Patel, Manish Umrethia, Jayanta Kumar Mandal
-
Patent number: 11931455Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: GrantFiled: July 31, 2023Date of Patent: March 19, 2024Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
-
Patent number: 11918684Abstract: The present invention provides pharmaceutical composition of immunosuppressive agent in oral suspension dosage form. The oral suspension composition comprises of immunosuppressive agent with other pharmaceutical excipients such as vehicle, suspending agent, solvent or cosolvent, preservative, sweetener, antifoaming agent, wetting agent, buffering agent and flavouring agent. The present invention oral suspension having improved stability, palatability with high dose of active ingredient. The present invention provides oral suspension with flavor that has masked bitter taste of the drug and eliminates difficulty of administration. Further, the present invention also provides a convenient, easy process for preparation thereof.Type: GrantFiled: March 12, 2018Date of Patent: March 5, 2024Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip Mehta, Manish Umrethia, Henil Patel, Jayanta Kumar Mandal
-
Publication number: 20230372238Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.Type: ApplicationFiled: July 31, 2023Publication date: November 23, 2023Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL